5348042025-07-012025-09-305348042025-09-305348042025-03-315348042025-04-012025-09-305348042025-07-012025-09-30in-capmkt:OtherExpenses1Member5348042025-04-012025-09-30in-capmkt:OtherExpenses1Member5348042025-07-012025-09-30in-capmkt:ReportableSegments1Member5348042025-07-012025-09-30in-capmkt:ReportableSegments2Member5348042025-04-012025-09-30in-capmkt:ReportableSegments1Member5348042025-04-012025-09-30in-capmkt:ReportableSegments2Member5348042025-07-012025-09-30in-capmkt:ReportableSegments1Member5348042025-07-012025-09-30in-capmkt:ReportableSegments2Member5348042025-04-012025-09-30in-capmkt:ReportableSegments1Member5348042025-04-012025-09-30in-capmkt:ReportableSegments2Member5348042025-07-012025-09-30in-capmkt:ReportableSegments1Member5348042025-09-30in-capmkt:ReportableSegments1Member5348042025-07-012025-09-30in-capmkt:ReportableSegments2Member5348042025-09-30in-capmkt:ReportableSegments2Member5348042025-07-012025-09-30in-capmkt:ReportableSegments1Member5348042025-09-30in-capmkt:ReportableSegments1Member5348042025-07-012025-09-30in-capmkt:ReportableSegments2Member5348042025-09-30in-capmkt:ReportableSegments2Member5348042025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15348042025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15348042025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15348042025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares534804CARERATINGNAINE752H01013CARE RATINGS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-122025-11-04INRLakhsQuarterlySecond quarterMulti segment2025-11-1212:00:002025-11-1218:00:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated1363711000125768000148947900000053280000061440003460100014682500072037000076910900007691090001965390004710001970100000572099000000057209900011949000584048000566686000541300057824900057990002999500001018.918.810018.918.810001. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on November 12, 2025 and have been subjected to limited review by the statutory auditors of the Company. <BR> <BR> 2. The consolidated financial results include results of CARE Ratings Limited and its subsidiaries namely CARE Analytics and Advisory Private Limited (formerly known as CARE Risk Solutions Private Limited), CARE ESG Ratings Limited (formerly known as CARE Advisory Research and Training Limited), CARE Ratings (Africa) Private Limited, CARE Ratings South Africa (Pty) Limited, CARE Ratings Nepal Limited and CareEdge Global IFSC Limited. <BR> <BR> 3. The accompanying financial results have been prepared as per the format prescribed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. <BR> <BR> 4. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) read with section 133 of the Companies Act, 2013. <BR> 2025-04-012025-09-30UnauditedConsolidated23027610002611760002563937000000106980400012138000685560002699310001420429000114350800001143508000300945000549000030643500008370730000000837073000822000084529300082447100012602000832486000128070002999500001027.5127.380027.5127.38000Other Expenses146825000Other Expenses26993100080971400000795030003160300003112200000145447700001096400094110000155955100013100016443000281249400002978980007973910002795700002586449000229670003329939000731421400065306000182894000756241400000103749080002999500008324011000862396100010316900087271300000000218530000218530000165040000697640000045333400000150018000150018000213877000363895000709001000491910007235700001194444000001647778000103749080005. The Company has alloted 36,899 equity shares of Rs.10 each pursuant to excercise of employee stock options during Q2 FY 25-26. As per Ind AS 102 - Share Based Payment, total cost of ESOS 2020 is recognised over vesting period. <BR> <BR> Employee Benefit Expenses in Consolidated results includes ESOP charge under respective periods as under: <BR> <BR> Share Based payment expenses: <BR> Quarter ended September 30, 2025 (unaudited) - 44.54 lakhs <BR> Half year ended September 30, 2025 (unaudited) - 111.56 lakhs <BR> <BR> 6. The Board of Directors of the Company have recommended interim dividend of Rs.8/- per share. <BR> <BR> 7. ESOP application money pending alloted included in other equity. <BR> Rating and related services1230138000Others135323000Rating and related services2059913000Others245257000136546100023051700001750000240900013637110002302761000Rating and related services755016000Others9104000Rating and related services1131687000Others-55160007641200001126171000614400012138000-11133000-294750007691090001143508000Rating and related services8086145000Others4568850008543030000183187800010374908000Rating and related services1261651000Others38612700016477780000164777800012138000000-9525200000-499815000000224152000068556000000-928710000-1701000202100023203100011156000-51420000-25880000-50790000-62049800052301000000026947900002535310000000000025880006446400000000000000242130000648646000000020210003585410000-57152000-164982000000831900000408060000006520003334660001213800000-297131000-2085820000-208582000488152000279570000Items that will not be reclassified to profit and loss11020001102000Items that will not be reclassified to profit and loss-3001000-3001000230000-690000Items that will be reclassified to profit and loss1107700011077000Items that will be reclassified to profit and loss105310001053100000119490008220000